IHE:ARCA-iShares U.S. Pharmaceutical (USD)

ETF | Health | NYSE Arca

Last Closing

USD 63.31

Change

0.00 (0.00)%

Market Cap

USD 0.69B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to track the investment results of Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying fund measures the performance of the pharmaceuticals sector of the U.S. equity market and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.

Inception Date: 01/05/2006

Primary Benchmark: DJ US Select Pharms TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.44%

Management Expense Ratio: 0.42 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
XLV Health Care Select Sector SPDR.. 0.13 %

-0.28 (-0.19%)

USD 40.26B
FHLC Fidelity® MSCI Health Care In.. 0.08 %

-0.13 (-0.18%)

USD 2.86B
FXH First Trust Health Care AlphaD.. 0.63 %

+0.33 (+0.31%)

USD 1.18B
XHE SPDR® S&P Health Care Equipme.. 0.35 %

+0.24 (+0.27%)

USD 0.21B
IDNA iShares Genomics Immunology an.. 0.00 %

+0.08 (+0.32%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF 0.50 %

-0.53 (-1.37%)

USD 0.12B
XHS SPDR® S&P Health Care Service.. 0.35 %

-1.28 (-1.35%)

USD 0.08B
HTEC Robo Global® Healthcare Techn.. 0.00 %

+0.12 (+0.43%)

USD 0.05B
BBP Virtus LifeSci Biotech Product.. 0.79 %

-0.56 (-0.87%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica.. 0.79 %

-0.55 (-1.87%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.44% 81% B- 57% F
Dividend Return 0.45% 100% F 26% F
Total Return 2.89% 86% B+ 54% F
Trailing 12 Months  
Capital Gain 4.80% 86% B+ 51% F
Dividend Return 1.50% 94% A 20% F
Total Return 6.30% 86% B+ 44% F
Trailing 5 Years  
Capital Gain 27.13% 53% F 64% D
Dividend Return 7.57% 89% A- 26% F
Total Return 34.70% 53% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 6.36% 38% F 62% D
Dividend Return 7.63% 52% F 59% D-
Total Return 1.27% 95% A 31% F
Risk Return Profile  
Volatility (Standard Deviation) 10.21% 100% F 81% B-
Risk Adjusted Return 74.76% 76% C+ 93% A
Market Capitalization 0.69B 52% F 50% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.